{"preliminary_commentary":{"by_channel":{"x_thread":2,"youtube":1,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"HER2 PARADIGM","nct_id":"NCT06750484","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=her2-paradigm-nct06750484. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"T-DXd will be administered intravenously every 3 weeks at a dose of 5.4 mg per kilogram of body weight until disease progression, limiting toxicity, withdrawal of consent, or death. For T-DXd, each cycle of treatment will be 21 days. The number of treatment cycles with T-DXd is not fixed.","label":"Trastuzumab Deruxtecan","type":"EXPERIMENTAL"}],"collaborators":["Daiichi Sankyo","AstraZeneca","Breast Cancer Research Foundation"],"completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"conditions":["Breast Cancer Metastatic"],"enrollment":{"count":40,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Trastuzumab Deruxtecan","otherNames":[],"type":"DRUG"}],"last_update":"2026-09-03","lead_sponsor":"Yale University","official_title":"Open-label Single-arm Phase 2 Trial of Trastuzumab Deruxtecan in Previously Treated HER2-Immunohistochemistry (IHC) 0 Advanced Breast Cancer","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Objective Response Rate","timeFrame":"After cycle 3, approximately 63 days"}],"references":[],"start_date":{"date":"2025-06-20","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Trial of Trastuzumab Deruxtecan in Previously Treated HER2","url":"https://clinicaltrials.gov/study/NCT06750484"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/her2-paradigm-nct06750484"}